FAST NEWS: Legend Biotech Terminates New Drug Trial Lacking Clinical Benefit
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), has terminated its Phase 1 Clinical Trial under the Investigational New Drug (IND) application for LB1901, due to…
FAST NEWS: CStone Submits New Drug Application, Grants Restricted Shares to Non-Executive Director
The latest: CStone Pharmaceuticals (2616.HK) announced it has reached the primary endpoint of its clinical study for its drug Cejemly to treat relapsed or refractory T-cell lymphoma, and plans to…
